Dohj LLC Acquires New Stake in Zoetis Inc. (NYSE:ZTS)

Dohj LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,504 shares of the company's stock, valued at approximately $408,000.

Several other large investors have also recently bought and sold shares of the company. State Street Corp raised its position in shares of Zoetis by 0.5% during the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company's stock valued at $3,864,488,000 after acquiring an additional 95,856 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company's stock valued at $2,030,813,000 after buying an additional 185,364 shares in the last quarter. Mizuho Securities USA LLC increased its holdings in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock worth $950,524,000 after purchasing an additional 4,829,815 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Zoetis by 5.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company's stock worth $761,221,000 after purchasing an additional 194,542 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Zoetis by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock worth $569,834,000 after purchasing an additional 279,092 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ZTS. Leerink Partners began coverage on Zoetis in a research report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 target price on the stock. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective for the company. Finally, Morgan Stanley reduced their price objective on Zoetis from $248.00 to $243.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis currently has an average rating of "Buy" and an average target price of $215.00.

Zoetis Price Performance

ZTS traded up $0.30 during trading on Tuesday, hitting $172.24. 2,696,175 shares of the stock traded hands, compared to its average volume of 2,685,644. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a market cap of $77.71 billion, a price-to-earnings ratio of 32.38, a PEG ratio of 2.72 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The business has a 50 day moving average price of $169.48 and a 200 day moving average price of $179.39.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the business earned $1.36 earnings per share. The company's revenue was up 11.6% on a year-over-year basis. Equities research analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. Zoetis's dividend payout ratio is 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.